NCT05293912 2025-03-18
SG2501 Safety Study in Subjects with Relapsed or Refractory Hematological Malignancies and Lymphoma.
Hangzhou Sumgen Biotech Co., Ltd.
Phase 1 Terminated
Hangzhou Sumgen Biotech Co., Ltd.
Seoul St. Mary's Hospital
Dartmouth-Hitchcock Medical Center